Understanding Your Laboratory Test: A Complete Patient Guide
This test uses FISH technology to detect specific genetic rearrangements in blood or tissue samples that may be associated with certain blood cancers.
{"Detects gene rearrangements in ABL1, ABL2, and PDGFRB genes","Helps diagnose and monitor certain leukemias and myeloproliferative neoplasms","Performed on a blood or tissue sample using fluorescence microscopy","Results help guide treatment decisions with targeted therapies","Abnormal results may indicate conditions like CML or other myeloproliferative disorders"}
Key facts at a glance
- LOINC
- 96494-0
- Short code
- ABL1/ABL2/PDGFRB FISH
- Synonyms
- ABL1 + ABL2 + PDGFRB rearr Bld/T FISH
- Category
- chemistry
- Sample
- whole-blood
- Container
- EDTA (purple top) tube for peripheral blood; tissue specimens should be submitted in sterile transport medium
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- ≥ 0 years
- Method
- Fluorescence In Situ Hybridization (FISH)
- CPT
- 88274,88275
- SNOMED
- 36773004,129133008,129133008
- Specimen volume
- 5-10 mL peripheral blood; tissue minimum 0.5 cm³
- Stability
- Blood: Process within 24-48 hours of collection, store at 2-8°C. Tissue: Process immediately, store at 2-8°C in transport medium.
- Hemolysis max
- 0
- Lipemia max
- 0
- Icterus max
- 0
- TAT
- 72–168 hours
- Order
- routine
This test is a laboratory analysis that helps your healthcare provider learn more about your health. It measures substances in a sample, such as blood or urine, to check how well your body is working and to look for possible signs of illness or disease.
The ABL1, ABL2, and PDGFRB Gene Rearrangement Test is a specialized diagnostic test that uses Fluorescence In Situ Hybridization (FISH) technology. This test looks for specific changes or rearrangements in three genes: ABL1, ABL2, and PDGFRB. These gene rearrangements can be important markers for certain blood cancers and disorders. The test is performed on a sample of whole blood or tissue, where fluorescent probes bind to specific parts of the genes, allowing scientists to see rearrangements under a special microscope.
Your doctor may order this test to help diagnose a medical condition, monitor an ongoing health problem, see how well a treatment is working, or screen for disease early, before you notice any symptoms.
This test is primarily used to help diagnose and monitor conditions such as chronic myeloid leukemia (CML), Philadelphia chromosome-positive leukemias, and other myeloproliferative neoplasms. It may also be used to guide treatment decisions, particularly for targeted therapies like tyrosine kinase inhibitors (TKIs). Additionally, the test can help distinguish between different types of blood disorders and assess how well treatment is working.
The test is done by collecting a small sample, most often blood drawn from a vein in your arm or a urine specimen. The sample is then sent to a laboratory, where trained technicians analyze it and report the findings back to your doctor.
A healthcare provider will collect a blood sample from a vein in your arm, or in some cases, a tissue sample may be obtained through a biopsy. The sample is then sent to a laboratory where specially trained technicians use FISH technology to examine the genes. The process involves adding fluorescent probes to the sample that attach to specific parts of the ABL1, ABL2, and PDGFRB genes. If rearrangements are present, the fluorescent patterns will appear different from normal, which can be detected and analyzed under a fluorescence microscope.
Your results show whether the measured values fall within the normal range for this test. Normal results usually suggest no sign of the condition being checked, while abnormal values may point to a health issue that needs closer evaluation. Always review your results with your doctor, who can explain what they mean for your specific situation.
Normal results mean no specific gene rearrangements were detected in the genes tested. Abnormal results indicate that rearrangements were found in one or more of the genes (ABL1, ABL2, or PDGFRB). These findings can help confirm a diagnosis of certain leukemias or myeloproliferative disorders. Your doctor will interpret these results in conjunction with other clinical findings, other test results, and your overall health condition to determine the best course of action.
Reference range
Negative for ABL1, ABL2, and PDGFRB gene rearrangements. No abnormal fusion signals detected.N/A
No special preparation required. Standard venipuncture procedure. Inform the laboratory if patient has received chemotherapy within the past 2-4 weeks as this may affect specimen quality.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
◆Associated findings1
Frequently asked questions
Do I need to prepare for this test?
Is the test painful?
How long does it take to get results?
What happens if my results are abnormal?
Will my insurance cover this test?
Sources
- 1
- 2
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy